Introduction
Familial or hereditary spastic paraplegia (HSP) is a group of clinically and genetically heterogeneous neurodegenerative disorders that share the primary features of slowly progressive spasticity and weakness of the lower limbs. Traditionally, HSP has been classified on the basis of the inheritance pattern, the age of onset, and the presence (complicated HSP) or absence (pure HSP) of additional neurological abnormalities such as mental retardation, dementia, ataxia, optic neuropathy, retinopathy, and so on. Although both forms can be inherited in an autosomal-dominant (AD-HSP), autosomal-recessive (AR-HSP) or X-chromosomelinked (X-HSP) manner, pure AD-HSP is the most common form of HSP (Fink et al. 1996; Harding 1983; Tallaksen et al. 2001) .
To date, seven genetic loci for pure AD-HSP have been mapped: chromosomes 14q (SPG3), 2p (SPG4), 15q (SPG6), 8q (SPG8), 12q (SPG10), 19q (SPG12), and 2q (SPG13). Among these loci, SPG4 is the most common and represents approximately 40% or more of pure AD-HSP cases (Casari and Rugarli 2001; Fink et al. 1996; Tallaksen et al. 2001) . Recently, Hazen et al. (1999) identified the spastin (SPG4) gene, which encodes a new member of the AAA (ATPase associated with diverse cellular activities) protein family. After this discovery, more than 70 mutations of the SPG4 gene have been reported, including missense, nonsense, and splice-site mutations, as well as insertions and deletions (Bürger et al. 2000; de Bantel et al. 2001; Fonknechten et al. 2000; Hazan et al. 1999; Hentati et al. 2000; Jiggins et al. 2001; Lindsey et al. 2000; Namekawa et al. 2001; Santorelli et al. 2000; Svenson et al. 2001) . Here, we present a novel missense (I344K) mutation in the SPG4 gene in a large Korean family with pure AD-HSP.
Subjects and methods

Case report
A 40-year-old male visited the neurology department complaining of weakness and spasticity in the lower extremities. He first noted stiffness of both legs and gait unsteadiness at age 33, and it had progressed over the years. His father and all of his siblings as well as many relatives on his father's side had similar problems (Fig. 1) . On neurological examination, his gait was spastic but independent. He was well oriented and had normal cognitive function without evidence of decreased visual acuity, optic neuropathy, retinopathy, pigmental macular degeneration, nystagmus, or dysarthria. Deep tendon reflex, muscle strength, tone, sensation, and coordination of upper extremities were normal. The lower extremity showed proximal and distal weakness, marked increase in tone, pathologically brisk reflexes, ankle clonus, and extensor plantar reflex, but normal sensation.
Clinical evaluation
After we had obtained informed consent, a detailed neurological examination including evaluation of the cranial nerves, deep tendon reflexes, motor, and sensory systems was performed on 14 additional family members of the proband. Information on deceased family members as well as on other family members who were not evaluated neurologically was obtained from the proband and other senior members of the family. Subjects were classified into four groups: (1) "definitely affected" if they had spasticity, increased reflexes, and extensor plantar response; (2) "probably affected" if they had only increased reflexes or extensor plantar response; (3) "possibly affected" if they had brisker reflexes in the lower limbs compared with the upper limbs; and (4) "normal" if they had no neurological abnormalities, as described previously . Disability was assessed on a five-point scale: 1, normal gait or very slight stiffness in the legs; 2, moderate gait stiffness; 3, unable to run but able to walk alone; 4, walk with help; 5, wheelchair bound .
Molecular genetic study
All 15 neurologically examined and 5 additional family members (4 were suspected to be affected and 1 was normal, based on the histories) were included in the molecular genetic study, after we obtained informed consent. Genomic DNA was isolated from peripheral blood leukocytes by using a Wizard Genomic DNA Purification kit following the manufacturer's instruction (Promega, Madison, WI, USA). Since SPG4 is the most common cause of pure AD-HSP and because it was the only locus with an identified gene, we decided to perform direct sequencing analysis of the SPG4 gene [during preparation of this article, however, Zhao et al. (2001) identified a second gene, SPG3A, causing early-onset AD-HSP]. By using the proband's DNA, all 17 exons of the SPG4 gene were amplified by polymerase chain reaction (PCR), as described previously (Hazan et al. 1999) . Cycle sequencing was performed with a BigDye Terminator Cycle Sequencing Ready Reaction kit, version 2.0. (Applied Biosystems, Foster City, CA, USA) on an automated ABI Prism 3100 genetic analyzer (Applied Biosystems). After finding a missense mutation in exon 7 of the SPG4 gene, a mismatch PCR-restriction fragment length polymorphism (RFLP) method was applied to confirm it. Since the mutation neither created nor destroyed a restriction site, we designed a mismatch primer (5Ј-ggaacagctgGtaaatttgatgTta-3Ј; underlined sequences indicate mismatched sites) to introduce a recognition sequence (ttaa) for MseI in the amplified DNA. The reverse primer was 5Ј-actactatggattcagtaacagatgg-3Ј. With this method, a 152-bp PCR product is divided into 129-and 23-bp fragments only with the mutant allele present, when treated with MseI (Fig. 2) .
Results
Clinical findings
Clinical features of affected individuals are summarized in Table 1 . Out of 15 family members examined neurologi- cally, 7 subjects were clinically affected. Among them, 2 subjects (III:14 and III:15) were classified as "definitely affected" because they had all of spasticity, hyperreflexia, and extensor plantar reflex. The others (IV:3, IV:4, IV:9, IV:11, and IV:13) were classified as "probably affected." Interestingly, 3 of the "probably affected" members (IV:3, IV:9, and IV:13) were unaware of any symptoms in the lower extremities. Only 1 subject (III:14) had sensory impairment of vibration and position in the lower extremities. None had cognitive dysfunction, cerebellar ataxia, parkinsonism, skin lesion, peripheral neuropathy, epilepsy, dysarthria, dystonia, urinary urgency, constipation, pes cavus, or visual symptoms. Age at onset was variable between 14 and 39 years (mean Ϯ SD, 28 Ϯ 10.7 years), and the initial symptom was the insidious appearance of stiffness in the legs for all the affected members. Regarding disability status, all the clinically affected subjects except the proband (III:15) were rated as stage 1. The proband was in stage 3 because he was unable to run but was able to walk alone.
Molecular genetic findings
By mutation analysis, we found a heterozygous T to A transversion in exon 7 of the SPG4 gene (c.1031TϾA), which alters the amino acid sequence from Ile to Lys at codon 344 (I344K; Fig. 2 ). All seven clinically affected family members had the missense mutation. Other family members with normal neurological findings did not have the mutation, except for two (IV:15 and IV:17), who were 15 and 8 years old (Fig. 1 ). They were thought to be asymptomatic mutation carriers in whom neurological signs of HSP had not developed at the time of the examination. Of interest, IV:15 had the subjective symptom of slight stiffness in the lower legs but showed normal neurological findings.
Among the five additional family members (II:7, III:9, III:12, III:17, and IV:7) tested for the mutation, the same heterozygous I344K mutation was found in all four individuals suspected to be affected from their history (II:7, III:12, III:17, and IV:7), but not in the one normal member (III:9). We confirmed the mutation by the mismatch PCR-RFLP method described above (Fig. 2) , and the mutation was not found in 100 normal chromosomes.
Discussion
Up to now, more than 70 mutations of the SPG4 gene have been described. Missense, nonsense, and splice-site mutations, as well as deletions and insertions, have all been observed. Although these mutations have been found scattered along the length of SPG4, the majority of the missense mutations are localized between exons 7 and 16 (Bürger et al. 2000; Fonknechten et al. 2000; Hazan et al. 1999; Hentati et al. 2000; Lindsey et al. 2000; Svenson et al. 2001 ). This region of SPG4 has been shown to correspond to a highly conserved ATPase domain, also called the AAA cassette,
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which is located between amino acids 342 and 599 of spastin (Hazan et al. 1999) . The importance of the AAA cassette in spastin function is suggested by its high degree of conservation among AAA protein family members and by the locations of the spastin gene mutations identified to date (Hazan et al. 1999; Svenson et al. 2001) .
The mutation described in the present study is also localized in exon 7 of the SPG4 gene, affecting the third amino acid of the highly conserved AAA cassette, which is the most fore part of the domain altered by a missense mutation reported so far. According to the multiple alignment results of eight proteins exhibiting high homology to human and mouse spastin, codon 344 is relatively well conserved in that only branched amino acids such as Ile and Val were observed (Hazan et al. 1999 ). The missense mutation I344K replaces Ile, a hydrophobic aliphatic amino acid, with Lys, a polar basic amino acid. Therefore, it seems likely that this change would severely reduce or abolish the function of the spastin protein (Bürger et al. 2000; Lindsey et al. 2000) .
The exact function of spastin is still not known. However, it has been found that the level of spastin mRNA tested in tissues from patients with SPG4 mutations is uniformly reduced. Therefore, the presumed loss of protein function by inactivation of the AAA domain because of different types of mutations in the SPG4 gene may be the possible pathogenic mechanism of HSP (Bürger et al. 2000; Fonknechten et al. 2000; Hazan et al. 1999; Lindsey et al. 2000) .
According to the recent review by Tallaksen et al. (2001) , the major clinical findings of 224 SPG4 mutation carriers are (1) almost 25% of gene carriers are asymptomatic; (2) the mean age at onset is 29 years, but ranges from the first year of life to 74 years; (3) disease progression is highly variable; (4) associated signs increase in frequency and/or severity with the duration of the disease; and (5) there is no apparent correlation between the type of mutation (missense versus truncating) and the clinical features. Clinical findings of affected individuals presented in this report are similar to those described above. In our study, 2 (15.4%) out of 13 family members carrying the I344K missense mutation were neurologically free. This percentage of asymptomatic carriers was somewhat lower than that reported in previous studies McMonagle et al. 2000; Tallaksen et al. 2001) . But this proportion could be increased to 38.5% if we added the three subjects who were not aware of any symptoms or signs. In our patients, mean age at onset was 28 years, which is consistent with previous data. Wide variation of disease progression was also noted.
It is noteworthy that the upper extremities as well as urinary function were relatively preserved in this family. In addition, sensory impairment was found in only one subject (III:14). All these features are common in AD-HSP patients carrying the SPG4 mutation. About 73% of patients with AD-HSP have hyperreflexia in the upper extremities, and 38%-59% of AD-HSP patients may be affected by urinary frequency, urgency, or hesitancy. Furthermore, sensory impairment, especially abnormal vibration sensations in the lower limb, is also a common presentation, found in 58%-68.2% of all AD-HSP patients with the SPG4 mutation McMonagle et al. 2000) .
In summary, we have identified a novel missense mutation in the SPG4 gene in a Korean family with pure AD-HSP. The clinical findings described in the present study may be useful in future genotype-phenotype correlation studies. To the best of our knowledge, this is the first report of genetically confirmed pure AD-HSP in Korea.
